



Mike Braun, Governor
State of Indiana

Indiana Family and Social Services Administration
Office of Medicaid Policy and Planning

402 W. WASHINGTON ST., ROOM W374, MS07
INDIANAPOLIS, IN 46204

MEETING AGENDA AND PUBLIC NOTIFICATION

Therapeutics Committee

November 7, 2025

11:00 A.M. EST

Hybrid Meeting

Indiana State Government Center South

Wabash Hall, Conference Rooms 4 & 5

Virtual Meeting Information Below

1. Call to Order-Chair
2. Preferred Drug List: Therapeutic Class Re-Review -
Discussion and Recommendations
3. Preferred Drug List: Therapeutic Class Re-Review
 - a) CNS and Others
 - i. Agents for the Treatment of Opioid Use
Disorder or Overdose
 - ii. Antiemetic/Antivertigo Agents
 - iii. Antiseizure Agents
 - iv. Gastroprotective Agents
 - v. Mental Health Agents
 1. Anti-Anxiety and Related Disorders
 2. Antidepressant Agents
 3. Antipsychotic and Antimanic Agents
 4. Alzheimer's and Dementia Agents



- 5. Insomnia Agents
- 6. Narcolepsy and Cataplexy Agents
- 7. Non-Stimulant ADHD Agents
- 8. Stimulants
- vi. Movement Disorder Agents
- vii. Narcotic Antitussives and Combinations
- viii. Narcotics
- ix. Skeletal Muscle Relaxants
- x. Smoking Deterrent Agents
- b) Dermatologic Agents
 - i. Acne Agents
 - ii. Antipsoriatics
- c) Endocrine
 - i. Anaphylaxis Agents
 - ii. Bone Formation Stimulating Agents
 - iii. Bone Resorption Inhibitors
 - iv. DPP-4 Inhibitors and Combination Agents
 - v. GLP-1 Receptor Agonists and Combinations
 - vi. Glucagon Agents
 - vii. Growth Hormones
 - viii. Insulins
 - ix. Miscellaneous Oral Antidiabetic Agents
 - x. SGLT Inhibitors and Combinations
 - xi. Testosterones
 - xii. Urea Cycle Disorders (Hyperammonemia Treatments)
- d) Estrogen and Related Agents
 - i. Estrogen and Related Agents
 - ii. Contraceptives
- e) Gastrointestinal Agents
 - i. Anti-ulcer Agents
 - ii. *H. Pylori* Agents

- iii. H2 Receptor Antagonists
- iv. Laxatives and Cathartics
- v. Pancreatic Enzymes
- vi. Proton Pump Inhibitors
- vii. Ulcerative Colitis Agents
- f) Genitourinary Agents
 - i. Benign Prostatic Hypertrophy Agents
 - ii. Urinary Tract Antispasmodic/Anti-Incontinence Agents
- g) Hematologic Agents
 - i. Direct Oral Anticoagulants
 - ii. Hematinics
 - iii. Leukocyte (WBC) Stimulants
 - iv. Platelet Aggregation Inhibitors
- h) Topical Agents
 - i. Dry Eye Disease or Keratoconjunctivitis
 - ii. Miotics-Intraocular Pressure Reducers
 - iii. Ophthalmic Antihistamines
 - iv. Ophthalmic Anti-Inflammatory Agents
 - v. Ophthalmic Mast Cell Stabilizers
 - vi. Otic Preparations
 - vii. Topical Anti-Inflammatory Agents-NSAIDs
 - viii. Topical Antiparasitics
 - ix. Topical Immunomodulators
 - x. Topical Post-herpetic Neuralgia Agents
- i) Drug Classes for SUPDL Consideration
 - i. Hereditary Angioedema
 - ii. Myasthenia Gravis
- 4. Public Comment
- 5. Other Business
- 6. Adjourn

Microsoft Teams [Need help?](#)

[Join the meeting now](#)

Meeting ID: 244 422 405 513

Passcode: DAoTyr

Dial in by phone

[+1 952-222-7450,,391682542#](#) United States, Minneapolis

[Find a local number](#)

Phone conference ID: 391 682 542#

Join on a video conferencing device

Tenant key: teams@optum.onpexip.com

Video ID: 111 408 641 77

[More info](#)
